Acute Agitation and Aggression Treatment Market is predicted to reach USD 9.40 billion at a CAGR of 6.95% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Acute Agitation and Aggression Treatment Market”.

The acute agitation and aggression treatment market is estimated to register a CAGR of 6.95% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global acute agitation and aggression treatment market— Eli Lilly and Company (US), Pfizer Inc (US), GlaxoSmithKline plc (UK), Teva Pharmaceutical Industries Ltd (Israel), Otsuka Holdings Co., Ltd (Japan), VIATRIS INC (US), Johnson & Johnson Services, Inc (US), Novartis AG (Switzerland), H. Lundbeck A/S (Denmark), and Amneal Pharmaceuticals LLC (US).

Acute Agitation and Aggression Treatment Market Highlights

The global acute agitation and aggression treatment market is accounted to register a CAGR of 6.95% during the forecast period and is estimated to reach USD 9.40 billion by 2032.

In recent years, increased focus on creating awareness about agitation and aggression has facilitated market growth. For instance, the Department of Health and Social Care (UK) organized a Prime Minister's challenge on dementia 2020. Nearly 1 million people have been educated to be Dementia Friends to raise awareness, and over 400,000 NHS employees and 100,000 social care workers have been taught to better support people with dementia in their communities. Moreover, industry associations and virtual events generate awareness about agitation and aggression. Conclusively, rising government initiatives will provide suitable backgrounds for the market to grow during the forecast period.

The rising prevalence of acute agitation and aggression and the increase in focus on creating awareness about agitation and aggression is propelling the market growth. However, the social stigma associated with mental illness, and shortage of trained and experienced psychiatrists is expected to hamper the growth of the global market. Nevertheless, ongoing research on the development of novel treatment for agitation is projected to create lucrative opportunities for market players.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Acute Agitation and Aggression Treatment  Market Research Report

Segment Analysis

The global acute agitation and aggression treatment market has been segmented based on the drug class, route of administration, indication, and end user.

On the basis of drug class, the market is segmented into first-generation anti-psychotics, second-generation anti-psychotics, benzodiazepines, and others. The second-generation anti-psychotics segment was attributed to holding the largest market share in 2022. The second-generation anti-psychotics segment was attributed to holding the largest market share in 2022 as estimated by MRFR analysts. This is due to the effective medication giving the best results for patients suffering from agitation and aggression, and other related disorders.

Further, we estimate that the market segment will continue to pool in the largest chunk of revenue during the forecast period. It has been identified that the segment market yet witnesses continuous innovations and movements in terms of new product launches.

Based on the route of administration, the global acute agitation and aggression treatment market has been segmented into oral, intramuscular, and others. The oral segment holds the largest market share in 2022.

Based on indication, the global acute agitation and aggression treatment market has been segmented into schizophrenia, dementia, bipolar disorder, depression, drug-induced agitation and aggression, alcohol withdrawal, and others. The dementia segment holds the largest market share in 2022.

On the basis of the end user, the market is segmented into hospitals & clinics, psychiatric care facilities, and others. The hospitals & clinics segment is projected to have the largest market share during the forecast period.

Regional Analysis

The global acute agitation and aggression treatment market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The Europe acute agitation and aggression treatment market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The acute agitation and aggression treatment market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the world acute agitation and aggression treatment market comprises of Middle East, Africa, and Latin America.

The growing modern healthcare infrastructure, widespread accessibility of innovative epigenetics products, extensive presence of major companies, and availability of qualified medical personnel, are boosting the growth of the North American region. Moreover, the growing burden of risk factors for agitation and aggression that include neurological disorders is further anticipated to bolster the market growth over the forecast period.

Moreover, the Europe market has been persistently growing owing to the rising awareness regarding treatments boosting the growth of the acute agitation and aggression treatment in the region.

Additionally, market factors, such as a rise in geriatric population and increase in agitation in patients, and ongoing research on the development of novel treatments for agitation in the Asia-Pacific region are driving the region’s growth.

Furthermore, the rest of the world acute agitation and aggression treatment market is divided into the Middle East, Africa, and Latin America. The main factors influencing the growth of acute agitation and aggression treatment in the Middle East and Africa are the increase in focus on creating awareness about agitation and aggression, and ongoing research on the development. In addition, governments in this region are also investing heavily in R&D activities to develop new and innovative products for cheek augmentation in the region. Moreover, growing partnerships between academic, pharmaceutical, and biotechnology companies expand the MEA acute agitation and aggression treatment market.

Key Findings of the Study

• The global acute agitation and aggression treatment market is expected to reach USD 9.40 billion by 2032, at a CAGR of 6.95% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market, owing to the rise in geriatric population and increase in agitation in patients, and ongoing research on the development of novel treatment for agitation in the region in the Asia-Pacific region.


• Based on indication, the dementia segment was attributed to holding the largest market in 2022, with an approximate market share of 45–65%.


• Eli Lilly and Company (US), Pfizer Inc (US), GlaxoSmithKline plc (UK), Teva Pharmaceutical Industries Ltd (Israel), Otsuka Holdings Co., Ltd (Japan), VIATRIS INC (US), Johnson & Johnson Services, Inc (US), Novartis AG (Switzerland), H. Lundbeck A/S (Denmark), and Amneal Pharmaceuticals LLC (US) are the key market players.